Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Sepúlveda, Mariaca
• dc.contributor.author Munteis Olivas, Elviraca
• dc.contributor.author Saiz, Albertca
• dc.date.accessioned 2018-07-03T08:19:56Z
• dc.date.available 2018-07-03T08:19:56Z
• dc.date.issued 2017
• dc.description.abstract BACKGROUND: Population-based studies on neuromyelitis optica spectrum disorders (NMOSD) are limited, and it is unclear whether the rates have changed with the implementation of the new 2015 criteria. OBJECTIVES: To estimate the incidence and prevalence of NMOSD in Catalonia (Spain), using both the 2006 and the 2015 criteria. METHODS: In this clinic-based retrospective study, patients diagnosed with NMOSD between 2006 and 2015 were identified using multiple sources, including direct contact to all Catalan hospitals, identification of cases through the Catalan Health Surveillance System, and registry of antibodies to aquaporin-4 (AQP4-IgG) and myelin oligodendrocyte glycoprotein (MOG-IgG) in a reference laboratory. The incidence rate was calculated for the period 1 January 2006-1 January 2016 and prevalence for the date 1 January 2016. RESULTS: We identified 74 patients (by the 2015 criteria). Most patients were Caucasian (81%), and female (76%) with a median age at disease onset of 42 years (range, 10-76 years). In total, 54 (73%) patients were positive for AQP4-IgG, 11 (15%) double-seronegative, and 9 (12%) MOG-IgG-positive. Rates of incidence and prevalence (0.63/1,000,000 person-years and 0.89/100,000, respectively) were 1.5-fold higher than those reported by the 2006 criteria. Lowest rates were seen in children and elder people and highest in women and middle-aged people (40-59 years). The female predominance was lost in incident AQP4-IgG-seronegative children and AQP4-IgG-positive elder people. MOG-IgG and double-seronegativity contributed similarly but did not influence the long-term outcome. CONCLUSION: The new criteria increase the estimates, but NMOSD remains as a rare disease. The differences in age- and sex-specific estimates highlight the importance of the serologic classification.
• dc.format.mimetype application/pdf
• dc.identifier.citation Sepúlveda M, Aldea M, Escudero D, Llufriu S, Arrambide G, Otero-Romero S. et al. Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates. Mult Scler. 2018; 24(14): 1843-1851. DOI: 10.1177/1352458517735191
• dc.identifier.doi http://dx.doi.org/10.1177/1352458517735191
• dc.identifier.issn 1352-4585
• dc.identifier.uri http://hdl.handle.net/10230/35021
• dc.language.iso eng
• dc.publisher SAGE Publicationsca
• dc.relation.ispartof Multiple Sclerosis Journal. 2018;24(14):1843-51
• dc.rights The final, definitive version of this paper has been published in Multiple sclerosis, Oct 1:1352458517735191 2017 by SAGE Publications Ltd, All rights reserved.
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.subject.keyword AQP4-antibodies
• dc.subject.keyword MOG-antibodies
• dc.subject.keyword Neuromyelitis optica spectrum disorders
• dc.subject.keyword Incidence
• dc.subject.keyword Prevalence
• dc.subject.other Immunoglobulines
• dc.subject.other Malalties rares (Catalunya)
• dc.title Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimatesca
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/acceptedVersion